FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023731256> ?p ?o ?g. }

• W2023731256 endingPage "108" @default.
• W2023731256 startingPage "101" @default.
• W2023731256 abstract "To verify the feasibility of 800 cGy of total body irradiation (TBI) with 120 mg/kg of cyclophosphamide (TBI-800/Cy-120) as a conditioning regimen for unrelated stem cell transplantation (u-SCT) in adult patients with severe aplastic anemia, we analyzed 50 consecutive patients who underwent u-SCT, including 26 patients from our previous pilot study. Seventeen patients received transplants from mismatched donors via high-resolution DNA typing (8 of 8). Thirty-eight patients received bone marrow and 12 peripheral blood stem cells (PBSCs). Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and short-course methotrexate. All patients achieved engraftment, and the median days of neutrophil and platelet recovery were 13 days and 20 days, respectively. The 5-year estimated overall survival was 88.0%. The cumulative incidences of acute grade II-IV GVHD (aGVHD) and chronic GVHD (cGVHD) were 46.0% and 50.3%, respectively. Only an HLA-mismatched donor was associated with the occurrence of aGVHD on multivariate analyses, whereas prior aGVHD and the use of PBSCs were associated with the occurrence of cGVHD on univariate analyses. In conclusion, the excellent outcomes of u-SCT with TBI-800/Cy-120 suggest that u-SCT may be applicable to patients with severe aplastic anemia even without prior treatment with immunosuppressive therapy, which will require testing in prospective trials in the future. To verify the feasibility of 800 cGy of total body irradiation (TBI) with 120 mg/kg of cyclophosphamide (TBI-800/Cy-120) as a conditioning regimen for unrelated stem cell transplantation (u-SCT) in adult patients with severe aplastic anemia, we analyzed 50 consecutive patients who underwent u-SCT, including 26 patients from our previous pilot study. Seventeen patients received transplants from mismatched donors via high-resolution DNA typing (8 of 8). Thirty-eight patients received bone marrow and 12 peripheral blood stem cells (PBSCs). Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and short-course methotrexate. All patients achieved engraftment, and the median days of neutrophil and platelet recovery were 13 days and 20 days, respectively. The 5-year estimated overall survival was 88.0%. The cumulative incidences of acute grade II-IV GVHD (aGVHD) and chronic GVHD (cGVHD) were 46.0% and 50.3%, respectively. Only an HLA-mismatched donor was associated with the occurrence of aGVHD on multivariate analyses, whereas prior aGVHD and the use of PBSCs were associated with the occurrence of cGVHD on univariate analyses. In conclusion, the excellent outcomes of u-SCT with TBI-800/Cy-120 suggest that u-SCT may be applicable to patients with severe aplastic anemia even without prior treatment with immunosuppressive therapy, which will require testing in prospective trials in the future." @default.
• W2023731256 created "2016-06-24" @default.
• W2023731256 creator A5002011050 @default.
• W2023731256 creator A5013163283 @default.
• W2023731256 creator A5036020306 @default.
• W2023731256 creator A5039667344 @default.
• W2023731256 creator A5044372572 @default.
• W2023731256 creator A5050627824 @default.
• W2023731256 creator A5060239856 @default.
• W2023731256 creator A5066664434 @default.
• W2023731256 creator A5068837815 @default.
• W2023731256 creator A5069563388 @default.
• W2023731256 creator A5085429434 @default.
• W2023731256 date "2011-01-01" @default.
• W2023731256 modified "2023-10-16" @default.
• W2023731256 title "The Outcome of Unrelated Hematopoietic Stem Cell Transplants with Total Body Irradiation (800 cGy) and Cyclophosphamide (120 mg/kg) in Adult Patients with Acquired Severe Aplastic Anemia" @default.
• W2023731256 cites W131854666 @default.
• W2023731256 cites W1530764705 @default.
• W2023731256 cites W1954992673 @default.
• W2023731256 cites W1980443079 @default.
• W2023731256 cites W2014400250 @default.
• W2023731256 cites W2016294085 @default.
• W2023731256 cites W2037894368 @default.
• W2023731256 cites W2037921839 @default.
• W2023731256 cites W2056235669 @default.
• W2023731256 cites W2058447377 @default.
• W2023731256 cites W2065505483 @default.
• W2023731256 cites W2073140442 @default.
• W2023731256 cites W2075002701 @default.
• W2023731256 cites W2076005731 @default.
• W2023731256 cites W2080380323 @default.
• W2023731256 cites W2088897722 @default.
• W2023731256 cites W2106456757 @default.
• W2023731256 cites W2119566322 @default.
• W2023731256 cites W2119784283 @default.
• W2023731256 cites W2129219275 @default.
• W2023731256 cites W2157626001 @default.
• W2023731256 cites W2158837255 @default.
• W2023731256 cites W2319873259 @default.
• W2023731256 cites W287410142 @default.
• W2023731256 cites W4230817393 @default.
• W2023731256 doi "https://doi.org/10.1016/j.bbmt.2010.06.014" @default.
• W2023731256 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20601037" @default.
• W2023731256 hasPublicationYear "2011" @default.
• W2023731256 type Work @default.
• W2023731256 sameAs 2023731256 @default.
• W2023731256 citedByCount "27" @default.
• W2023731256 countsByYear W20237312562012 @default.
• W2023731256 countsByYear W20237312562013 @default.
• W2023731256 countsByYear W20237312562014 @default.
• W2023731256 countsByYear W20237312562015 @default.
• W2023731256 countsByYear W20237312562016 @default.
• W2023731256 countsByYear W20237312562017 @default.
• W2023731256 countsByYear W20237312562018 @default.
• W2023731256 countsByYear W20237312562019 @default.
• W2023731256 countsByYear W20237312562020 @default.
• W2023731256 crossrefType "journal-article" @default.
• W2023731256 hasAuthorship W2023731256A5002011050 @default.
• W2023731256 hasAuthorship W2023731256A5013163283 @default.
• W2023731256 hasAuthorship W2023731256A5036020306 @default.
• W2023731256 hasAuthorship W2023731256A5039667344 @default.
• W2023731256 hasAuthorship W2023731256A5044372572 @default.
• W2023731256 hasAuthorship W2023731256A5050627824 @default.
• W2023731256 hasAuthorship W2023731256A5060239856 @default.
• W2023731256 hasAuthorship W2023731256A5066664434 @default.
• W2023731256 hasAuthorship W2023731256A5068837815 @default.
• W2023731256 hasAuthorship W2023731256A5069563388 @default.
• W2023731256 hasAuthorship W2023731256A5085429434 @default.
• W2023731256 hasBestOaLocation W20237312561 @default.
• W2023731256 hasConcept C126322002 @default.
• W2023731256 hasConcept C141071460 @default.
• W2023731256 hasConcept C144301174 @default.
• W2023731256 hasConcept C2776694085 @default.
• W2023731256 hasConcept C2776755627 @default.
• W2023731256 hasConcept C2777408962 @default.
• W2023731256 hasConcept C2778880498 @default.
• W2023731256 hasConcept C2779263901 @default.
• W2023731256 hasConcept C2780007613 @default.
• W2023731256 hasConcept C2780611847 @default.
• W2023731256 hasConcept C2781440808 @default.
• W2023731256 hasConcept C28328180 @default.
• W2023731256 hasConcept C2911091166 @default.
• W2023731256 hasConcept C38180746 @default.
• W2023731256 hasConcept C54355233 @default.
• W2023731256 hasConcept C71924100 @default.
• W2023731256 hasConcept C86803240 @default.
• W2023731256 hasConcept C90924648 @default.
• W2023731256 hasConceptScore W2023731256C126322002 @default.
• W2023731256 hasConceptScore W2023731256C141071460 @default.
• W2023731256 hasConceptScore W2023731256C144301174 @default.
• W2023731256 hasConceptScore W2023731256C2776694085 @default.
• W2023731256 hasConceptScore W2023731256C2776755627 @default.
• W2023731256 hasConceptScore W2023731256C2777408962 @default.
• W2023731256 hasConceptScore W2023731256C2778880498 @default.
• W2023731256 hasConceptScore W2023731256C2779263901 @default.
• W2023731256 hasConceptScore W2023731256C2780007613 @default.
• W2023731256 hasConceptScore W2023731256C2780611847 @default.
• W2023731256 hasConceptScore W2023731256C2781440808 @default.

• next